Skip to search formSkip to main contentSkip to account menu

ATI 7505

Known as: ATI-7505, ATI7505, naronapride 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

BenzamidesQuinuclidinesSerotonin 5-HT4 Receptor Agonists

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
A Multi-Center, Double-Blind, Parallel-Group Study to Evaluate Short-Term Safety and Efficacy and Long-Term Maintenance of Two Dose Levels of Rabeprazole Sodium Delayed-Release Pediatric Bead…
2011
2011
The Pharmacokinetics and Tolerability of Naronapride, a 5-HT4 Receptor Agonist, in Healthy Subjects
Review
2011
Review
2011
A Phase II, Randomized, Double-Blind, Placebo Controlled, Three Period, Crossover, Single Center Study to Evaluate the Effects of Naronapride on Esophageal and Gastric pH and Reflux Events in…
2010
2010
Comments on Tegaserod Trial on Irritable Bowel Syndrome
TO THE EDITOR: Irritable bowel syndrome (IBS) remains to be a challenge for the gastroenterologist, due to its high prevalence… 
2010
2010
S1033 Results of a Thorough QT Study (ICH E14) Testing a Novel Gastrointestinal Prokinetic, ATI-7505, Show NO ECG Effects at Therapeutic and Supra-Therapeutic Doses
2009
2009
158 Efficacy of ATI-7505, a Novel Highly Selective 5-HT4 Receptor Agonist, in a Rodent Model of Colonic Hypersensitivity.
2006
2006
The GERD market
Gastroesophageal reflux disease (GERD) occurs when stomach contents flow into the esophagus. GERD sufferers often complain of a… 
2006
2006
Gateways to clinical trials.
101M, 12B75; ABT-869, Agomelatine, Alvocidib hydrochloride, Amb a 1 ISS-1018, AMG-386, Andolast, AP-23573, Arsenic trioxide, ATI… 
2005
2005
Cardiac Safety and Phase I Clinical Data for ATI-7505, a Selective 5-HT4 Receptor Agonist: 105
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)